No abstract

Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, including ADH1A, ADH1C, CA12, CHP2, HMGCS2, SNAR-A1, TPI1, MS4A12, PLA2G10 and PTPRO , were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period.

In recent years, the intervention of pharmacists in the proper use of eye drops in the elderly has led to improved adherence. It is also said to have been effective in preventing postoperative complications, preventing infections and avoiding adverse events. However, con rmation of eye drops adherence is subjective patient information. For this reason, it is often impossible to con rm the actual procedure, and it is not clear whether it was used correctly. Therefore, we conducted questionnaire surveys of patients undergoing cataract surgery to con rm the instillation status. In addition, we measured the weight of the ophthalmic solution after use and considered the relationship with the questionnaire. The subjects of the questionnaire were elderly people aged over 70 years old. The eye drops techniques were the upper and lower opening method (44.3 ), the lower eyelid drooping method (42.3 ), and others (13.4 ). Subjects replied that they were generally properly instilled. As a result of measuring the solution weight, the actual value of the Moxi oxacin ophthalmic solution was signi cantly less than the appropriate value (P < 0.01). In addition, as a result of multivariate analysis, the factor that decreased the eye drops weight by more than 5 was the patient who answered, I can't apply well (OR: 5.98, 95 CI: 1.31 -35.29, P = 0.021). The subjective information of the elderly may be unreliable. Therefore, we need to conduct detailed interviews about the situation of instillation. In addition, training of techniques and periodic re-evaluation will lead to optimization and improvement of eye drops adherence.